Rare immuno-mediated adverse events: literature review


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

Immune checkpoint inhibitors have heralded the advent of a “new era" in cancer treatment, significantly improving long-term survival of patients. While these novel agents are often well tolerated, they are widely known to cause a unique profile of immune-mediated toxicities. Any organ systems can be harmed be immune therapy, but the skin, gastro-intestinal tract, liver, lungs and endocrine system are most commonly affected. In recent years, an increasing number of atypical and sometimes life-threatening side effects have been reported, which requires early recognition and prompt intervention. This article reviews rare immune-related adverse events, their diagnosis and management.

Texto integral

Acesso é fechado

Sobre autores

E. Degtiareva

N.N. Petrov National Medical Research Center of Oncology

Email: degtyarevaekaterina@mail.ru
Oncologist, Postgraduate student at the Scientific Department of Innovative Methods of Therapeutic Oncology and Rehabilitation 68, Leningradskaya str., Pesochny settlement, St. Petersburg 197758, Russian Federation

S. Protsenko

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

E. Imyanitov

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

Bibliografia

  1. Schoenfeld S.R., Aronow M.E., Leaf R.K., et al. Diagnosis and Management of Rare Immune-Related Adverse Events. Oncologist. 2020;25(1):6-14. doi: 10.1634/theoncologist.2019-0083.
  2. Kim J.M., Materin M.A., Sznol M., et al. Ophthalmic Immune-Related Adverse Events of Immunotherapy: A Single-Site Case Series. Ophthalmology. 2019;126(7):1058-62. doi: 10.1016/j.ophtha.2019.01.031.
  3. Fang T, Maberley D.A., and Etminanb M. Ocular adverse events with immune checkpoint inhibitors. J Curr Ophthalmol. 2019;31(3):319-22. doi: 10.1016/j.joco.2019.05.002.
  4. Michel L, Rassaf T., Totzeck M. Cardiotoxicity from immune checkpoint inhibitors. IJC Heart & Vasculature. 2019;25:100420. Doi: 10.1016/j. ijcha.2019.100420.
  5. Agrawal N, Khunger A., Vachhani P, et al. Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: Case Series and Review of the Literature. Case Rep Oncol. 2019;12:260-76. doi: 10.1159/000498985.
  6. Johnson D.B., Balko J.M., Compton M.L., et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375(18):1749-55. Doi: 10.1056/ NEJMoa1609214.
  7. Mahmood S.S., Fradley M.G., Cohen J.V., et al. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol. 2018;71(16):1755-64. Doi: 10.1016/j. jacc.2018.02.037.
  8. Moslehi J.J., Salem J.E., Sosman J.A., et al. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet. 2019; 391 (10124):933. doi: 10.1016/s0140-6736(18)30533-6.
  9. Upadhrasta S., Elias H., Patel K., et al. Managing cardiotoxicity associated with immune checkpoint inhibitors. Chronic Dis Transl Med. 2019;5(1):6-14. doi: 10.1016/j.cdtm.2019.02.004.
  10. National Comprehensive Cancer Network, Clinical Practice Guidelines in Oncology (NCCN Guidelines®), Management of Immunotherapy-Related Toxicities, Version 1.2020 - December 16, 2019. Accessed at https://www.nccn.org/ professionals/physician_gls/pdf/immunotherapy. pdf on Februrary 25, 2020.
  11. Curigliano G., Lenihan D., Fradley M., et al. Management of Cardiac Disease in Cancer Patients Throughout Oncological Treatment: ESMO Consensus Recommendations. Ann Oncol. 2020;31(2):171-90. Doi: 10.1016/j. annonc.2019.10.023.
  12. Saade A., Mansuet-Lupo A., Arrondeau J., et al. Pericardial effusion under nivolumab: case-reports and review of the literature. J Immunother Cancer. 2019;7:266. doi: 10.1186/s40425-019-0760-4.
  13. Khan A., Zhang H., Chen C., et al. Impact of pericardial effusion for patients receiving immune checkpoint inhibitors. J Clin Oncol. 2019;37:e14121-e14121. Doi: 10.1200/ JCO.2019.37.15_suppl.e14121.
  14. Shaheen S., Mirshahidi H., Nagaraj G., et al. Conservative management of nivolumab-induced pericardial effusion: a case report and review of literature. Exp Hematol Oncol 2018;7:11. doi: 10.1186/s40164-018-0104-y.
  15. Chen D.Y, Huang W.K., Chien-Chia Wu V., et al. Cardiovascular toxicity of immune checkpoint inhibitors in cancer patients: A review when cardiology meets immunooncology. J Formos Med Assoc. 2019;pii:S0929-6646(19)30408-5. doi: 10.1016/j.jfma.2019.07.025.
  16. Ederhy S., Cautela J., Ancedy Y, et al. Takotsubo-like syndrome in cancer patients treated with immune checkpoint inhibitors. JACC Cardiovasc Imaging 2018;11(18):1187-90. Doi: 10.1016/j. jcmg.2017.11.036.
  17. Lyon A.R., Yousaf N., Battisti N.M.L., et al. Immune checkpoint inhibitors and cardiovascular toxicity. Lancet Oncol. 2018;19(9):e447-e458. doi: 10.1016/S1470-2045(18)30457-1.
  18. Cautela J., Rouby F., Salem J.E., et al. Acute coronary syndrome with immune checkpoint inhibitors: a proof-of-concept case and pharmacovigilance analysis of a life-threatening adverse event. Can J Cardiol 2020;36(4):476-81. Doi: 10.1016/j. cjca.2019.11.035
  19. Al-Kindi S.G., Oliveira G.H. Prevalence of preexisting cardiovascular disease in patients with different types of cancer: the unmet need for oncocardiology. Mayo Clin Proc 2016;91(1):81-3. doi: 10.1016/j.mayocp.2015.09.009
  20. Gelsomino F., Fiorentino M., Zompatori M., et al. Programmeddeath-1inhibitionandatherosclerosis: can nivolumab vanish complicated atheromatous plaques? Ann. Oncol. 2018;29(1):284-86. doi: 10.1093/annonc/mdx718
  21. Daxini A., Cronin K. and Sreih A.G. Vasculitis associated with immune checkpoint inhibitors - a systematic review. Clin Rheumatol. 2018;37:2579-84. doi: 10.1007/s10067-018- 4177-0
  22. Jamal S., Hudson M., Fifi-Mah A., et al. Immunerelated Adverse Events Associated with Cancer Immunotherapy: A Review for the Practicing Rheumatologist. J Rheumatol. 2020;47:166-75. doi: 10.3899/jrheum.190084
  23. Reynolds K.L., Guidon A.C. Diagnosis and Management of Immune Checkpoint InhibitorAssociated Neurologic Toxicity: Illustrative Case and Review of the Literature. Oncologist. 2019;24(4):435-43. Doi: 10.1634/ theoncologist.2018-0359
  24. Connolly C., Bambhania K. and Naidoo J. Immune Related Adverse Events: A Case-Based Approach. Front Oncol. 2019;9:530. Doi: 10.3389/ fonc.2019.00530
  25. Möhn N., Beutel G., Gutzmer R., et al. Neurological Immune Related Adverse Events Associated with Nivolumab, Ipilimumab, and Pembrolizumab Therapy-Review of the Literature and Future Outlook. J Clin Med. 2019;8(11):1777. doi: 10.3390/jcm8111777
  26. Cuzzubbo S., Javeri F., Tissier M., et al. Neurological adverse events associated with immune checkpoint 20 inhibitors: Review of the literature. Eur J Cancer. 2017;73:1-8. doi: 10.1016/j.ejca.2016.12.001
  27. Johnson D.B., Manouchehri A., Haugh A.M., et al. Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study. J Immunother Cancer. 2020;7(1):134. doi: 10.1186/s40425-019-0617-x
  28. Safa H., Johnson D.H., Trinh V.A., et al. Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature. J Immunother Cancer. 2019;7(1):319. doi: 10.1186/s40425-019- 0774-y
  29. Gravbrot N., Scherer K. and Sundararajan S. Safe Transition to Pembrolizumab following Ipilimumab-Induced Guillain-Barré Syndrome: A Case Report and Review of the Literature. Case Rep Oncol Med. 2019;2019:5490707. doi: 10.1155/2019/5490707
  30. Gaudy-Marqueste C., Monestier S., Franques J., et al. A severe case of ipilimumab-induced GuillainBarre syndrome revealed by an occlusive enteric neuropathy: a differential diagnosis for ipilimumabinduced colitis. J Immunother. 2013;36(1):77-8. doi: 10.1097/CJI.0b013e31827807dd
  31. Bhatia S.,Huber B.R.,Upton M.P.,etal.Inflammatory enteric neuropathy with severe constipation after ipilimumab treatment for melanoma: a case report. J Immunother. 2009;32(2):203-5. doi: 10.1097/CJI.0b013e318193a206
  32. Brahmer J.R., Lacchetti C., Schneider B.J., et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36:1714-68. Doi: 10.1200/ JCO.2017.77.6385
  33. Haanen J., Carbonnel F., Robert C., et al. Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv119-42. doi: 10.1093/annonc/ mdx225

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bionika Media, 2020

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies